This study evaluates a new aqueous nasal formulation of ipratropium bromide (Atrovent Nasal Spray 0.03%) in subjects with perennial non-allergic rhinitis in a double-blind, placebo-controlled trial.

Ipratropium bromide 0.03% (21mcg/spray); aqueous soln ... secretions from the serous and seromucous glands lining the nasal mucosa when applied locally. Epistaxis, pharyngitis, nasal dryness ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln ... secretions from the serous and seromucous glands lining the nasal mucosa when applied locally. <5yrs: not recommended.